Literature DB >> 28271661

Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women.

Ye-Li Yao1, Qi-Fang Tian1, Bei Cheng1, Yi-Fan Cheng1, Jing Ye1, Wei-Guo Lu1.   

Abstract

Cytology triage has been generally recommended for human papillomavirus (HPV)-positive women, but is highly dependent on well-trained cytologists. The present study was designed to explore whether HPV E6/E7 mRNA detection in cervical exfoliated cells can be a potential triage for HPV-positive women from a clinic-based population. Both the primary HPV testing and Papanicolaou (Pap) test were performed on all eligible HPV-positive women. HPV E6/E7 mRNA was detected by QuantiVirus® HPV E6/E7 mRNA assay in cervical exfoliated cells. All HPV-positive women underwent colposcopy and further biopsy if indicated. The data were assessed by Pearson's Chi-squared test and the receiver operating characteristic curve. A total of 404 eligible HPV-positive women were enrolled. Positive rate of E6/E7 mRNA in high-grade squamous intraepithelial lesion (HSIL) cases was higher than that in low-grade squamous intraepithelial lesion (LSIL) or normal cases. There was no statistical difference found between mRNA and cytological testing with sensitivity (89.52% vs. 86.67%, P=0.671), specificity (48.96% vs. 48.96%, P=1.000), positive predictive value (39.00% vs. 38.24%, P=1.000), and negative predictive value (92.76% vs. 90.97%, P=0.678) for detecting ≥HSIL. HPV E6/E7 mRNA detection in cervical exfoliated cells shows the same performance as Pap triage for HSIL identification for HPV-positive women. Detection of HPV E6/E7 mRNA may be used as a new triage option for HPV-positive women.

Entities:  

Keywords:  HPV E6/E7 mRNA; High-grade squamous intraepithelial lesion (HSIL); Human papillomavirus (HPV)

Mesh:

Substances:

Year:  2017        PMID: 28271661      PMCID: PMC5369250          DOI: 10.1631/jzus.B1600288

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  31 in total

1.  Papanicolaou tests diagnosed as atypical by a cytotechnologist and downgraded to benign by a pathologist: a measure of laboratory quality.

Authors:  Jennifer L Condel; Laura K Mahood; Dana M Grzybicki; Charles D Sturgis; Stephen S Raab
Journal:  Am J Clin Pathol       Date:  2002-04       Impact factor: 2.493

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

Review 3.  Human papillomavirus infection: biology, epidemiology, and prevention.

Authors:  M E Scheurer; G Tortolero-Luna; K Adler-Storthz
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

4.  Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA.

Authors:  Gerald Coquillard; Bibiana Palao; Bruce K Patterson
Journal:  Gynecol Oncol       Date:  2010-10-14       Impact factor: 5.482

5.  Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.

Authors:  Maria Benevolo; Amina Vocaturo; Donatella Caraceni; Deborah French; Sandra Rosini; Roberta Zappacosta; Irene Terrenato; Lucia Ciccocioppo; Antonio Frega; Paolo Giorgi Rossi
Journal:  J Clin Microbiol       Date:  2011-04-27       Impact factor: 5.948

6.  Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.

Authors:  Roberta Zappacosta; Donatella Caraceni; Lucia Ciccocioppo; Tiziana Rotondo; Serena Capanna; Daniela Maria Pia Gatta; Chiara D'Angelo; Sandra Rosini
Journal:  Gynecol Oncol       Date:  2012-11-28       Impact factor: 5.482

7.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

8.  Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.

Authors:  S Chellappan; V B Kraus; B Kroger; K Munger; P M Howley; W C Phelps; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

9.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

Authors:  Henry C Kitchener; Maribel Almonte; Claire Thomson; Paula Wheeler; Alexandra Sargent; Boyka Stoykova; Clare Gilham; Helene Baysson; Christopher Roberts; Robin Dowie; Mina Desai; Jean Mather; Andrew Bailey; Andrew Turner; Sue Moss; Julian Peto
Journal:  Lancet Oncol       Date:  2009-06-17       Impact factor: 41.316

10.  HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.

Authors:  Sveinung Wergeland Sørbye; Marc Arbyn; Silje Fismen; Tore Jarl Gutteberg; Elin Synnøve Mortensen
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

View more
  7 in total

1.  Women's health and Chinese integrative medicine.

Authors:  Fan Qu; Fang-Fang Wang; Nicola Robinson; Paul J Hardiman
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

2.  Diagnostic Utility of HPV16 E6 mRNA or E7 mRNA Quantitative Expression for Cervical Cells of Patients with Dysplasia and Carcinoma.

Authors:  Ming-Zhe Wu; Wei-Nan Li; Na Cha; Li-Xiang Tian; Y I Zhang; Xin Wu; Ke-Jun Guo; Guang-Ping Wu
Journal:  Cell Transplant       Date:  2018-07-30       Impact factor: 4.064

3.  Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS.

Authors:  Yuanhang Zhu; Chenchen Ren; Li Yang; Xiaoan Zhang; Ling Liu; Zhaoxin Wang
Journal:  BMC Cancer       Date:  2019-03-27       Impact factor: 4.430

4.  Bee venom inhibits the proliferation and migration of cervical-cancer cells in an HPV E6/E7-dependent manner.

Authors:  Da-Hyun Kim; Hyun-Woo Lee; Hyun-Woo Park; Han-Woong Lee; Kyung-Hee Chun
Journal:  BMB Rep       Date:  2020-08       Impact factor: 4.778

Review 5.  Detection of Host Cell Gene/HPV DNA Methylation Markers: A Promising Triage Approach for Cervical Cancer.

Authors:  Lingyi Zhang; Wenxi Tan; Hongmei Yang; Songling Zhang; Yun Dai
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

6.  Evaluation of HPV E6/E7 mRNA Detection in Clinically Suspected Cases of Cervical Cancer with Abnormal Cytology: Time to Upgrade the Screening Protocols.

Authors:  Bhawna Sharma; Vikas Lakhanpal; Kanwardeep Singh; Loveena Oberoi; Preet Kamal Bedi; Pushpa Devi
Journal:  J Lab Physicians       Date:  2022-07-04

7.  Prognostic and diagnostic validity of p16/Ki-67, HPV E6/E7 mRNA, and HPV DNA in women with ASCUS: a follow-up study.

Authors:  Chenchen Ren; Yuanhang Zhu; Li Yang; Xiaoan Zhang; Ling Liu; Zhaoxin Wang; Dongyuan Jiang
Journal:  Virol J       Date:  2019-11-21       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.